The effect of eldecalcitol on bone mineral density and bone markers for osteoporotic patients with type 2 diabetes.-Open label multicenter study

Not Applicable

• Conditions: osteoporosis

• Registration Number: JPRN-UMIN000008417
• Lead Sponsor: Shimane University Faculty of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-07-17
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Pending
• Sex: Female
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

1.Patients who have taken bisphosphonate treatments 2.Patients who have taken medicine such as SERMs, glucocorticoid, vitamin K, active vitamin D, calcitonin, insulin within two months from the day of eldecalcitol dosage 3.Patients who are inappropriate for this study by physician

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1.Change of lumbar spine bone mineral density 2.Change of total hip bone mineral density

Secondary Outcome Measures

Name	Time	Method
1.X-ray of thoracolumbar(Number of fracture occurred) 2.Body composition 3.Blood and urinaly biochemical test(FBS, HbA1c, IRI, CRP, Cr, CK, CRP, Alb, Ca, P, T-Chol, Homocysteine, Pentosidine, Adiponectin, Sclerostin, esRAGE, DKK-1, 25(OH)D, Urinaly Ca, Urinaly Cr, Urinaly Alb, Urinaly NTX) 4.Muscular strength/Balance function test(Grasping power, Open eyes standing on one leg test) 5.Safety